Skip to main content
. 2018 Jan 25;23(5):594–602. doi: 10.1634/theoncologist.2017-0328

Table 2. Key favorable and unfavorable effects for DRd versus Rd and for DVd versus Vd.

image

The data cutoff for the MMY3003 study was March 7, 2016, and the data cutoff for the MMY3004 study was January 11, 2016.

Abbreviations: CI, confidence interval; DRd, daratumumab + lenalidomide + low‐dose dexamethasone; DVd, daratumumab + bortezomib + low‐dose dexamethasone; HR, hazard ratio; MRD, minimal residual disease; NA, not applicable; NE, not estimated; PFS, progression‐free survival; Rd, lenalidomide + low‐dose dexamethasone; Vd, bortezomib + low‐dose dexamethasone.